Medication Adherence in Multiple Sclerosis As a Potential Model for Other Chronic Diseases: a Population-Based Cohort Study.

Charity Evans,Ruth Ann Marrie,Shenzhen Yao,Feng Zhu,Randy Walld,Helen Tremlett,David Blackburn,Elaine Kingwell
DOI: https://doi.org/10.1136/bmjopen-2020-043930
IF: 3.006
2021-01-01
BMJ Open
Abstract:OBJECTIVE:To determine whether better medication adherence in multiple sclerosis (MS) might be due to specialised disease-modifying drug (DMD) support programmes by: (1) establishing higher adherence in MS than in other chronic diseases and (2) determining if higher adherence is associated with patient-specific or treatment-specific factors.DESIGN:Retrospective cohort study with data from 1 January 1996 to 31 December 2015.SETTING:Population-based health administrative data from three Canadian provinces.PARTICIPANTS:Individual cohorts were created using validated case definitions for MS, epilepsy, Parkinson's disease (PD) and rheumatoid arthritis (RA). Subjects were included if they received ≥1 dispensation for a disease-related drug between 1 January 1997 and 31 December 2014.MAIN OUTCOME MEASURES:Proportion of subjects with optimal adherence (≥80%) measured by the medication possession ratio 1 year after the index date (first dispensation of disease-related drug).RESULTS:126 478 subjects were included in the primary analysis (MS, n=6271; epilepsy, n=55 739; PD, n=21 304; RA, n=43 164). Subjects with epilepsy (adjusted OR, aOR 0.29; 95% CI 0.19 to 0.45), PD (aOR 0.42; 95% CI 0.29 to 0.63) or RA (aOR 0.26; 95% CI 0.19 to 0.35) were less likely to have optimal 1-year adherence compared with subjects with MS. Within the MS cohort, adherence was higher for DMD than for chronic-use non-MS medications, and no consistent patient-related predictors of adherence were observed across all four non-MS medication classes, including having optimal adherence to DMD.CONCLUSIONS:Subjects with MS were significantly more likely to have optimal 1-year adherence than subjects with epilepsy, RA and PD, and optimal adherence appears related to treatment-specific factors rather than patient-related factors. This supports the hypothesis that higher adherence to the MS DMDs could be due to the specialised support programmes; these programmes may serve as a model for use in other chronic conditions.
What problem does this paper attempt to address?